Prosecution Insights
Last updated: April 19, 2026

Senju Pharmaceutical Co. Ltd.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18269837 NRF2-ACTIVATING COMPOUND KIFLE, BRUCK 1624 Final Rejection Jun 27, 2023
17831843 THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM SCHMITT, MICHAEL J 1629 Final Rejection Jun 03, 2022
17610844 COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE STEELE, AMBER D 1658 Non-Final OA Nov 12, 2021

Managing Senju Pharmaceutical Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month